SARS-CoV-2 Vaccine Development: An Overview and Perspectives | ACS Pharmacology & Translational Science
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses | npj Vaccines
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Developing COVID-19 Vaccines in Record Time NAIIS – 5/12/2020 1
Vaccines for COVID‐19 - Tregoning - 2020 - Clinical & Experimental Immunology - Wiley Online Library
P00081 Modification to MCDC OTA No. W150KN-16-9-1002 BETWEEN JANSSEN PHARMACEUTICALS, INC. 1125 TRENTON-HARBOURTON ROAD TITUSVIL
J&J Seeks EUA for COVID-19 Vaccine
Advances in gene-based vaccine platforms to address the COVID-19 pandemic - ScienceDirect
University of Chicago Medicine begins recruiting participants for phase 3 COVID-19 investigational vaccine clinical trial - UChicago Medicine
J&J working with Beth Israel to accelerate COVID-19 vaccine developmen
Frontiers | A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
Johnson & Johnson (Janssen Pharmaceutical Cos.) - Single-Shot COVID-19 Vaccine (formerly JNJ-78436735, Ad26.COV2.S)
.png "Comparing COVID-19 Vaccines - ChemistryViews")
Comparing COVID-19 Vaccines - ChemistryViews
J&J Submits EUA For Single-Shot Janssen COVID Vax Candidate | Contract Pharma
